About Navitor Pharmaceuticals

Navitor’s mission is to discover and develop a new class of medicines that restore normal activity to mTORC1 to treat age-related diseases and improve human health. Our pioneering medicines are designed to selectively target mTORC1 (mechanistic target of rapamycin complex 1), the master regulator of cellular function and a key mechanism in age-related diseases.

Navitor’s drug discovery platform leverages recent discoveries in mTORC1 biology, along with proprietary know-how and intellectual property, to create medicines that address key targets that regulate mTORC1 activity.

With our primary pipeline focus on age-related diseases, our novel medicines are designed to inhibit – or “turn down” – mTORC1 activity that is excessive in age-related conditions, such as diabetic kidney disease.  We also pursue select opportunities in chronic diseases where our deep scientific insights have shown that activating – or “turning up” – mTORC1 can treat diseases, such as poor cognitive function and depression, in which suppressed mTORC1 activity starves tissues of needed energy and function. Navitor’s most advanced clinical candidate is a first-in-class therapy for major depressive disorder.

Our world-class team and proprietary technology stems from on groundbreaking discoveries made by Navitor’s scientific founder, Dr. David Sabatini, MD, PhD, of the Whitehead Institute for Biomedical Research. Navitor is led by an experienced management team and a world-class scientific advisory board with a proven track record for discovering innovative medicines and building successful drug development companies. With our unique capabilities for targeting mTORC1, we are pursuing an unprecedented and powerful therapeutic approach to address unmet needs in age-related diseases.

Back to Top